MDxHealth SA (MDXH)Healthcare | Diagnostics & Research | Herstal, Belgium | NasdaqCM
2.31 USD
+0.11
(5.000%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.35 +0.04 (1.732%) ⇧ (April 17, 2026, 4:16 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 1:19 p.m. EDT
MDXH exhibits strong short-term bearish momentum with a recent price decline and negative fundamentals, suggesting a strong short signal. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.140290 |
| AutoARIMA | 0.140309 |
| AutoTheta | 0.140320 |
| MSTL | 0.145652 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 60.06 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 2.159 |
| Market Cap | 118,652,040 |
| Forward P/E | -17.77 |
| Beta | -537543.56 |
| Profit Margins | -31.07% |
| Website | https://mdxhealth.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.44375002 |
| Address1 | CAP Business Center |
| Address2 | Rue d’Abhooz 31 Zone Industrielle des Hauts-Sarts |
| All Time High | 13.17 |
| All Time Low | 0.35 |
| Ask | 2.39 |
| Ask Size | 3 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 253,020 |
| Average Daily Volume3 Month | 160,512 |
| Average Volume | 160,512 |
| Average Volume10Days | 253,020 |
| Beta | -537,543.56 |
| Bid | 2.26 |
| Bid Size | 3 |
| Board Risk | 7 |
| Book Value | -0.235 |
| City | Herstal |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | Belgium |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.31 |
| Current Ratio | 1.078 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.35 |
| Day Low | 2.2 |
| Earnings Call Timestamp End | 1,772,141,400 |
| Earnings Call Timestamp Start | 1,772,141,400 |
| Earnings Timestamp | 1,778,788,800 |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda | -7,059,000 |
| Ebitda Margins | -0.06544 |
| Enterprise To Ebitda | -24.95 |
| Enterprise To Revenue | 1.633 |
| Enterprise Value | 176,121,040 |
| Eps Current Year | -0.32 |
| Eps Forward | -0.13 |
| Eps Trailing Twelve Months | -0.67 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.0164 |
| Fifty Day Average Change | -0.70640016 |
| Fifty Day Average Change Percent | -0.23418649 |
| Fifty Two Week Change Percent | 44.375004 |
| Fifty Two Week High | 5.33 |
| Fifty Two Week High Change | -3.02 |
| Fifty Two Week High Change Percent | -0.56660414 |
| Fifty Two Week Low | 1.552 |
| Fifty Two Week Low Change | 0.7579999 |
| Fifty Two Week Low Change Percent | 0.48840198 |
| Fifty Two Week Range | 1.552 - 5.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,636,032,600,000 |
| Float Shares | 35,684,473 |
| Forward Eps | -0.13 |
| Forward P E | -17.769232 |
| Free Cashflow | -3,658,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 364 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.6455 |
| Gross Profits | 69,633,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11184 |
| Held Percent Institutions | 0.49593 |
| Implied Shares Outstanding | 51,364,520 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Ipo Expected Date | 2,021-11-04 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It also offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium. |
| Long Name | MDxHealth SA |
| Market | us_market |
| Market Cap | 118,652,040 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_4803148 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -33,519,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 117,624,750 |
| Number Of Analyst Opinions | 5 |
| Open | 2.2 |
| Operating Cashflow | -2,189,000 |
| Operating Margins | -0.17809999 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 866 259 5644 |
| Post Market Change | 0.03999996 |
| Post Market Change Percent | 1.7316002 |
| Post Market Price | 2.35 |
| Post Market Time | 1,776,456,962 |
| Previous Close | 2.2 |
| Price Eps Current Year | -7.21875 |
| Price Hint | 4 |
| Price To Book | -9.829787 |
| Price To Sales Trailing12 Months | 1.099903 |
| Profit Margins | -0.31072 |
| Quick Ratio | 0.886 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.11 |
| Regular Market Change Percent | 5.0 |
| Regular Market Day High | 2.35 |
| Regular Market Day Low | 2.2 |
| Regular Market Day Range | 2.2 - 2.35 |
| Regular Market Open | 2.2 |
| Regular Market Previous Close | 2.2 |
| Regular Market Price | 2.31 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 80,904 |
| Return On Assets | -0.05899 |
| Return On Equity | -24.40408 |
| Revenue Growth | 0.194 |
| Revenue Per Share | 2.159 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 51,364,520 |
| Shares Percent Shares Out | 0.0014 |
| Shares Short | 73,632 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 17,033 |
| Short Name | MDxHealth SA |
| Short Percent Of Float | 0.0019 |
| Short Ratio | 0.45 |
| Source Interval | 15 |
| Symbol | MDXH |
| Target High Price | 9.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 7.4 |
| Target Median Price | 7.0 |
| Total Cash | 29,135,000 |
| Total Cash Per Share | 0.567 |
| Total Debt | 86,604,000 |
| Total Revenue | 107,875,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.402275 |
| Two Hundred Day Average Change | -1.0922751 |
| Two Hundred Day Average Change Percent | -0.32104257 |
| Type Disp | Equity |
| Volume | 80,904 |
| Website | https://mdxhealth.com |
| Zip | 4,040 |